Status:
COMPLETED
Surgical Outcome of HCC With Portal Vein Tumor Thrombosis on the Basis of Risk Scoring
Lead Sponsor:
Keimyung University Dongsan Medical Center
Conditions:
Hepatocellular Carcinoma
Portal Vein Thrombosis
Eligibility:
All Genders
Brief Summary
The goal of this multicenter retrospective cohort study is to investigate the clinical outcomes and prognostic factors after hepatic resection in patients with HCC exhibiting PVTT, and to develop a pr...
Detailed Description
Hepatocellular carcinoma (HCC) frequently invades the surrounding liver vasculature, with portal vein tumor thrombosis (PVTT) being the most common form of macrovascular invasion. At the time of HCC d...
Eligibility Criteria
Inclusion
- The patients underwent liver resection for HCC with portal vein tumor thrombosis between Jan 2005 and Dec 2019 at 10 university-affiliated hospitals in South Korea.
Exclusion
- Metastatic cancer \& extrahepatic metastasis
- Intrahepatic cholangiocarcinoma
- Mixed type hepatocellular-cholangiocarcinoma
- Recurred hepatocellular carcinoma
- not available medical records.
- Child-Pugh classification B or C
Key Trial Info
Start Date :
April 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 10 2022
Estimated Enrollment :
332 Patients enrolled
Trial Details
Trial ID
NCT06005883
Start Date
April 10 2021
End Date
April 10 2022
Last Update
August 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Keimyung university Dongsan Medical Center
Daegu, DalSeo-gu, South Korea, 42601